Validea Detailed Fundamental Analysis

Validea's Partha Mohanram P/B Growth Investor model assigns Johnson & Johnson (JNJ) an 88% rating, indicating strong interest for the large-cap Biotechnology & Drugs firm. This strategy, known for identifying low book-to-market stocks with sustained growth potential and historical market outperformance, highlights JNJ's fundamental strength, despite noting a 'fail' in the company's research and development to assets metric.

Analysis

Johnson & Johnson (JNJ) has received a high rating of 88% from Validea's P/B Growth Investor model, a quantitative strategy developed by Partha Mohanram to identify low book-to-market stocks with fundamentals indicative of sustained growth. This score suggests strong interest from the model, positioning JNJ as a promising large-cap growth stock within the Biotechnology & Drugs industry. The company successfully passed eight distinct fundamental tests, demonstrating strength in key areas such as Return on Assets (ROA), Cash Flow from Operations to Assets, and stability metrics including ROA and Sales Variance. This broad-based success points to solid operational performance and financial health. However, the analysis also flags a notable weakness, as JNJ failed the test for Research and Development to Assets. For a company in the biotech and drug sector, this particular metric's failure warrants attention as it could have implications for the firm's long-term innovation pipeline, despite its otherwise robust fundamental profile.

Key Decisions for Investors

• Investors should view the 88% score from the Partha Mohanram model as a strong quantitative signal supporting a bullish thesis on JNJ, based on its favorable growth and value characteristics.
• The specific failure on the 'Research and Development to Assets' metric requires further due diligence, and investors should scrutinize JNJ's R&D pipeline and productivity to assess any potential risk to long-term growth.
• Given the model's focus on identifying 'winners' among low book-to-market stocks, value-oriented growth investors may find the report validates JNJ as a potentially attractive investment at its current valuation.